BACKGROUND: ABCG2 is a high-capacity urate transporter that plays a crucial role in renal urate overload and extra-renal urate underexcretion. Previous studies have suggested an association between hyperuricemia and gout susceptibility relative to dysfunctional ABCG2 variants, with rs2231142 (Q141K) being the most common. In this study, we analyzed the ABCG2 gene in a hyperuricemia and gout cohort focusing on patients with pediatric-onset, i.e., before 18 years of age. METHOD: The cohort was recruited from the Czech Republic (n = 234) and consisted of 58 primary hyperuricemia and 176 gout patients, with a focus on pediatric-onset patients (n = 31, 17 hyperuricemia/14 gouts); 115 normouricemic controls were used for comparison. We amplified, sequenced, and analyzed 15 ABCG2 exons. The chi-square goodness-of-fit test was used to compare minor allele frequencies (MAF), and the log-rank test was used to compare empirical distribution functions. RESULTS: In the pediatric-onset cohort, two common (p.V12M, p.Q141K) and three very rare (p.K360del, p.T421A, p.T434M) allelic ABCG2 variants were detected. The MAF of p.Q141K was 38.7% compared to adult-onset MAF 21.2% (OR = 2.4, P = 0.005), to the normouricemic controls cohort MAF 8.5% (OR = 6.8, P < 0.0001), and to the European population MAF 9.4% (OR = 5.7, P < 0.0001). The MAF was greatly elevated not only among pediatric-onset gout patients (42.9%) but also among patients with hyperuricemia (35.3%). Most (74%) of the pediatric-onset patients had affected family members (61% were first-degree relatives). CONCLUSION: Our results show that genetic factors affecting ABCG2 function should be routinely considered in a hyperuricemia/gout diagnosis, especially in pediatric-onset patients. Genotyping of ABCG2 is essential for risk estimation of gout/hyperuricemia in patients with very early-onset and/or a family history.

Department of Pediatrics and Adolescent Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czech Republic

Department of Rheumatology 1st Faculty of Medicine Charles University Prague Czech Republic

Institute of Rheumatology Na Slupi 4 128 50 Prague 2 Czech Republic

Zobrazit více v PubMed

Zhu Y, Pandya BJ, Choi HK. Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008. Arthritis Rheum. 2011;63:3136–3141. doi: 10.1002/art.30520. PubMed DOI

Hak AE, Curhan GC, Grodstein F, et al. Menopause, postmenopausal hormone use and risk of incident gout. Ann Rheum Dis. 2010;69(7):1305–1309. doi: 10.1136/ard.2009.109884. PubMed DOI PMC

Harrold LR, Yood RA, Mikuls TR, et al. Sex differences in gout epidemiology: evaluation and treatment. Ann Rheum Dis. 2006;65(10):1368–1372. doi: 10.1136/ard.2006.051649. PubMed DOI PMC

Harrold LR, Etzel CJ, Gibofsky A, et al. Sex differences in gout characteristics: tailoring care for women and men. BMC Musculoskelet Disord. 2017;18(1):108. doi: 10.1186/s12891-017-1465-9. PubMed DOI PMC

Zikánová M, Wahezi D, Hay A, et al. Clinical manifestations and molecular aspects of phosphoribosylpyrophosphate synthetase superactivity in females. Rheumatology (Oxford) 2018;57(7):1180–1185. doi: 10.1093/rheumatology/key041. PubMed DOI PMC

Kostalova E, Pavelka K, Vlaskova H, et al. Hyperuricemia and gout due to deficiency of hypoxanthine-guanine phosphoribosyltransferase in female carriers: new insight to differential diagnosis. Clin Chim Acta. 2015;440:214–217. doi: 10.1016/j.cca.2014.11.026. PubMed DOI

Tang W, Miller MB, Rich SS, et al. Linkage analysis of a composite factor for the multiple metabolic syndrome: the National Heart, Lung, and Blood Institute Family Heart Study. Diabetes. 2003;52(11):2840–2847. doi: 10.2337/diabetes.52.11.2840. PubMed DOI

Wilk JB, Djousse L, Borecki I, et al. Segregation analysis of serum uric acid in the NHLBI Family Heart Study. Hum Genet. 2000;106(3):355–359. doi: 10.1007/s004390051050. PubMed DOI

Yang Q, Guo CY, Cupples LA, et al. Genome-wide search for genes affecting serum uric acid levels: the Framingham Heart Study. Metabolism. 2005;54(11):1435–1434. doi: 10.1016/j.metabol.2005.05.007. PubMed DOI

Köttgen A, Albrecht E, Teumer A, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet. 2013;45(2):145–154. doi: 10.1038/ng.2500. PubMed DOI PMC

Nakayama A, Nakaoka H, Yamamoto K, et al. GWAS of clinically defined gout and subtypes identifies multiple susceptibility loci that include urate transporter genes. Ann Rheum Dis. 2017;76(5):869–877. doi: 10.1136/annrheumdis-2016-209632. PubMed DOI PMC

Ichida K, Matsuo H, Takada T, et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun. 2012;3(3):764. doi: 10.1038/ncomms1756. PubMed DOI PMC

Vivante A, Hildebrandt F. Exploring the genetic basis of early-onset chronic kidney disease. Nat Rev Nephrol. 2016;12(3):133–146. doi: 10.1038/nrneph.2015.205. PubMed DOI PMC

Matsuo H, Ichida K, Takada T, et al. Common dysfunctional variants in ABCG2 are a major cause of early-onset gout. Sci Rep. 2013;3:2014. doi: 10.1038/srep02014. PubMed DOI PMC

Stiburkova B, Pavelcova K, Zavada J, et al. Functional non-synonymous variants of ABCG2 and gout risk. Rheumatology (Oxford) 2017;56(11):1982–1992. doi: 10.1093/rheumatology/kex295. PubMed DOI

Sakiyama M, Matsuo H, Takada Y, et al. Ethnic differences in ATPbinding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions. Drug Metab Pharmacokinet. 2014;29(6):490–492. doi: 10.2133/dmpk.DMPK-14-SC-041. PubMed DOI

Nakayama A, Matsuo H, Nakaoka H, et al. Common dysfunctional variants of ABCG2 have stronger impact on hyperuricemia progression than typical environmental risk factors. Sci Rep. 2014;4:5227. doi: 10.1038/srep05227. PubMed DOI PMC

Matsuo H, Yamamoto K, Nakaoka H, et al. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. Ann Rheum Dis. 2016;75(4):652–659. doi: 10.1136/annrheumdis-2014-206191. PubMed DOI PMC

Li C, Li Z, Liu S, et al. Genome-wide association analysis identifies three new risk loci for gout arthritis in Han Chinese. Nat Commun. 2015;13(6):7041. doi: 10.1038/ncomms8041. PubMed DOI PMC

Matsuo H, Takada T, Ichida K, et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med. 2009;1:5ra11. doi: 10.1126/scitranslmed.3000237. PubMed DOI

Higashino T, Takada T, Nakaoka H, et al. Multiple common and rare variants of ABCG2 cause gout. RMD Open. 2017;3(2):e000464. doi: 10.1136/rmdopen-2017-000464. PubMed DOI PMC

Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum. 1977;20(3):895–900. doi: 10.1002/art.1780200320. PubMed DOI

Woodward OM, Köttgen A, Coresh J, et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A. 2009;106(25):10338–10342. doi: 10.1073/pnas.0901249106. PubMed DOI PMC

Abhishek A, Courtney P, Jenkins W, et al. Monosodium urate crystal deposits are common in asymptomatic sons of people with gout - the sons of gout study. Arthritis Rheumatol. 2018;70(11):1847–1852. doi: 10.1002/art.40572. PubMed DOI PMC

Voruganti VS, Laston S, Haack K, et al. Serum uric acid concentrations and SLC2A9 genetic variation in Hispanic children: the Viva La Familia study. Am J Clin Nutr. 2015;101(4):725–732. doi: 10.3945/ajcn.114.095364. PubMed DOI PMC

Hurba O, Mancikova A, Krylov V, et al. Complex analysis of urate transporters SLC2A9, SLC22A12 and functional characterization of non-synonymous allelic variants of GLUT9 in the Czech population: no evidence of effect on hyperuricemia and gout. PLoS One. 2014;9(9):e107902. doi: 10.1371/journal.pone.0107902. PubMed DOI PMC

Maliepaard M, Scheffer GL, Faneyte IF, et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001;61(8):3458–3464. PubMed

Matsuo H, Nakayama A, Sakiyama M, et al. ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload. Sci Rep. 2014;4:3755. doi: 10.1038/srep03755. PubMed DOI PMC

Roberts RL, Wallace MC, Phipps-Green AJ, et al. ABCG2 loss-of-function polymorphism predicts poor response to allopurinol in patients with gout. Pharmacogenomics J. 2016;17(2):201–203. doi: 10.1038/tpj.2015.101. PubMed DOI

Wen CC, Yee SW, Liang X, et al. Genome-wide association study identifies ABCG2 (BCRP) as an allopurinol transporter and a determinant of drug response. Clin Pharmacol Ther. 2015;97(5):518–525. doi: 10.1002/cpt.89. PubMed DOI PMC

Petru L, Pavelcova K, Sebesta I, Stiburkova B. Genetic background of uric acid metabolism in a patient with severe chronic tophaceous gout. Clin Chim Acta. 2016;460:46–49. doi: 10.1016/j.cca.2016.06.007. PubMed DOI

Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis & Rheum. 2002;47(6):610–613. doi: 10.1002/art.10792. PubMed DOI

Kannangara DRW, Phipps-Green AJ, Dalbeth N, et al. Hyperuricaemia: contributions of urate transporter ABCG2 and the fractional renal clearance of urate. Ann Rheum Dis. 2016;75(7):1363–1366. doi: 10.1136/annrheumdis-2015-208111. PubMed DOI

Stamp L, Dalbeth N. Urate-lowering therapy for asymptomatic hyperuricaemia: a need for caution. Semin Arthritis Rheum. 2017;46(4):457–464. doi: 10.1016/j.semarthrit.2016.07.015. PubMed DOI

Examining the Association of Rare Allelic Variants in Urate Transporters SLC22A11, SLC22A13, and SLC17A1 with Hyperuricemia and Gout

Functional Characterization of Rare Variants in OAT1/SLC22A6 and OAT3/SLC22A8 Urate Transporters Identified in a Gout and Hyperuricemia Cohort

Identification of Two Dysfunctional Variants in the ABCG2 Urate Transporter Associated with Pediatric-Onset of Familial Hyperuricemia and Early-Onset Gout

Evaluation of the Influence of Genetic Variants of SLC2A9 (GLUT9) and SLC22A12 (URAT1) on the Development of Hyperuricemia and Gout

Interaction of the p.Q141K Variant of the ABCG2 Gene with Clinical Data and Cytokine Levels in Primary Hyperuricemia and Gout

Familial early-onset hyperuricemia and gout associated with a newly identified dysfunctional variant in urate transporter ABCG2

Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort